Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Keratoconus Epidemiology Forecast Report 2017-2030 - ResearchAndMarkets.com

January 6, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jan 6, 2021--

The “Keratoconus - Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Keratoconus (KC) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Keratoconus (KC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Keratoconus (KC) Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of KC in the seven major markets was estimated to be 1,602,427 in 2017.
  • The diagnosed prevalent cases of KC, in the United States, were found to be 550,047 in 2017.
  • In 2017, the mild, moderate and severe type of KC, in the United States, were found to be 121,010, 313,527, and 115,510, respectively.
  • It was found that in the United States, the maximum number of cases of KC was found in the age group of 30-39 with 181,515 cases in 2017, while the lowest number of cases were found in the age group ≥ 60 with 16,501 cases in 2017.
  • In the EU5 countries, the diagnosed prevalence of KC was found to be maximum in Germany, with 218,772 cases, followed by Italy with 171,676 cases in 2017. The least number of cases were found in Spain, with 105,463 cases in 2017.
  • In Japan, the diagnosed prevalence of KC was anticipated to be 240,591 in 2017.

Report Highlights

  • Eleven Year Forecast of Keratoconus (KC)
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of Keratoconus (KC)
  • As per the publisher’s analysis, KC, based on its severity, can be categorized into three types, namely, mild, moderate and severe.
  • The publisher has also analysed age-specific data of KC, according to which the overall diagnosed population of KC can be segmented into separate age groups, namely, < 20, 20-29, 30-39, 40-49, 50-59, and ≥ 60. Further analysis of this data suggests that KC is more prevalent among the 30-39 age group.
  • The current treatment option for KC includes Intrastromal corneal ring segments (ICRS), Corneal reshaping and Cross-Linking (CXL) along with Riboflavin solutions + UV Light, Keratoplasty and Others (Antihistamine/mast cell-stabilizing topical medications, antihistamines, mast cell stabilizers, nonsteroidal anti-inflammatory (NSAID)).
  • The emerging pipeline of KC market possess only one therapy, namely, IVMED-80 Eye Drop, which is being developed by iVeena Delivery Systems. It is non-surgical, non-UV light treatment for medical cross-linking of the cornea. This therapy is currently in its phase I/II clinical developmental stage.


Key Questions Answered

  • What is the disease risk, burden and unmet needs of Keratoconus (KC)?
  • What is the historical Keratoconus (KC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Keratoconus (KC) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Keratoconus (KC)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Keratoconus (KC) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1 Key Insights

2 Keratoconus (KC) Overview at a Glance

3 Executive Summary of Keratoconus (KC)

4 Disease Background and Overview: Keratoconus (KC)

4.1 Introduction

4.2 Types of KC

4.2.1 Shape-based differentiation

4.2.2 Severity- based differentiation

4.2.3 Index-based differentiation

4.3 Causes

4.4 Signs and Symptoms

4.5 Pathology

4.6 Histopathology

4.6.1 Epithelium

4.6.2 Basement membrane

4.6.3 Nerve fibers

4.6.4 Bowman’s layer

4.6.5 Stroma

4.7 Diagnosis

4.7.1 Eye refraction

4.7.2 Slit-lamp examination

4.7.3 Keratometry

4.7.4 Corneal Topography

4.7.5 Corneal Tomography

4.7.6 Keratoconus indices

4.7.7 The Belin Ambrosio Enhanced Ectasia Display (BAD)

4.7.8 Holladay 6 map display

4.7.9 Corneal pachymetry

4.7.10 Automated detection program for subclinical KC

4.7.11 Corneal biomechanics

4.8 Differential Diagnosis

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 Total Diagnosed Prevalent Population of Keratoconus in the 7MM

6 Country-wise Epidemiology of Keratoconus

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Total Diagnosed Prevalent Population of Keratoconus in the United States

6.1.3 Severity-specific Distribution of Keratoconus in the United States

6.1.4 Age-specific Distribution of Keratoconus in the United States

6.2 EU5 Countries

6.2.1 Assumptions and Rationale

6.3 Germany

6.4 France

6.5 Italy

6.6 Spain

6.7 United Kingdom

6.8 Japan

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/a5s64o

View source version on businesswire.com:https://www.businesswire.com/news/home/20210106005565/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 01/06/2021 10:27 AM/DISC: 01/06/2021 10:28 AM